Publication Name	World Journal of Gastroenterology
Manuscript ID	31541
Country	United States

Received	2016-11-24 11:57
Peer-Review Started	2016-11-25 11:48
To Make the First Decision	2016-12-19 09:54
Return for Revision	2016-12-24 19:05
Revised	2017-01-05 02:55
Second Decision	2017-02-15 18:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-02-17 10:06
Articles in Press	2017-02-17 10:07
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-03-02 16:34
Publish the Manuscript Online	2017-03-19 18:45

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Insights on the use of biosimilars in the treatment of inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Michael K Zheng, David Q Shih and Gary C Chen
Funding Agency and Grant Number
Corresponding Author	Gary C Chen, MD, Comprehensive Digestive Institute of Nevada, 8530 West Sunset Road, Suite 230, Las Vegas, NV 89113, United States. garychen@nevadagastro.com
Key Words	Biosimilar; Biologic; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Indication extrapolation; Interchangeability
Core Tip	The expiration of patent protection for various biologics and increasing health care expenses has paved the way for biosimilars to enter the market. The introduction of biosimilars is expected to produce cost savings in the health care industry as well as provide patients with inflammatory bowel disease with wider access to treatment.
Publish Date	2017-03-19 18:45
Citation	Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(11): 1932-1943
URL	http://www.wjgnet.com/1007-9327/full/v23/i11/1932.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i11.1932

Full Article (PDF)	WJG-23-1932.pdf
Full Article (Word)	WJG-23-1932.doc
Manuscript File	31541-Review.docx
Answering Reviewers	31541-Answering reviewers.pdf
Audio Core Tip	31541-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	31541-Conflict-of-interest statement.pdf
Copyright License Agreement	31541-Copyright assignment.pdf
Peer-review Report	31541-Peer-review(s).pdf
Scientific Misconduct Check	31541-Scientific misconduct check.pdf
Scientific Editor Work List	31541-Scientific editor work list.pdf